Introduction
============

Nasopharyngeal carcinoma (NPC) is the most common head and neck malignancy, which is endemic in Southeast Asia.[@b1-cmar-10-1419] Over 60,600 new cases were diagnosed and almost 34,100 patients were dead in China in 2015.[@b2-cmar-10-1419] Also, 60%--70% of patients are diagnosed with locoregionally advanced nasopharyngeal carcinoma (LANPC).[@b3-cmar-10-1419],[@b4-cmar-10-1419] Based on the anatomical location and radiosensitivity, radiotherapy (RT) is the primary therapeutic regimen for NPC. With RT alone, the 5-year overall survival (OS) rate for stage I is \>90%. However, the 5-year OS rate is only 67%--77% in LANPC treated with RT alone.[@b5-cmar-10-1419] In the era of two-dimensional RT (2D-RT), several studies have shown that the addition of concurrent chemotherapy to radiation improves local control and OS.[@b6-cmar-10-1419]--[@b9-cmar-10-1419] Thus, concurrent chemoradiotherapy (CCRT) is the standard therapeutic model recommended by the National Comprehensive Cancer Network guideline.

Intensity-modulated radiotherapy (IMRT) has brought a great progress in the treatment of LANPC. It provides better tumor target coverage with lower radiation-associated toxicities than 2D-RT, and thus, the locoregional control has been substantially improved.[@b10-cmar-10-1419],[@b11-cmar-10-1419] Meanwhile, as reported, IMRT alone can achieve the same or similar treatment effect and significantly decrease the adverse reactions in patients with LANPC, compared with the 2D-RT combined with chemotherapy. The 3-year OS rate was 80.43% for IMRT alone and 74% for 2D-RT combined with chemotherapy.[@b12-cmar-10-1419] Furthermore, Sun et al reported that by the addition of concurrent chemotherapy to IMRT, no survival benefits were observed in the 5-year disease-specific survival, local recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival in 603 NPC patients with stage III--IVb.[@b13-cmar-10-1419] What is more, more treatment-associated toxicities were observed in CCRT group than in IMRT alone group. Similarly, Lin et al found that compared with IMRT alone, CCRT provided no obvious clinical benefit and induced significantly higher grade 3--4 acute toxicities in 370 LANPC patients.[@b14-cmar-10-1419] On the contrary, Xie et al reported that the addition of concurrent chemotherapy increased the estimated 5-year OS rate from 73.7% (without concurrent chemotherapy) to 81.8% (with concurrent chemotherapy), but was accompanied with increased toxicities.[@b15-cmar-10-1419] Thus, it is controversial whether the addition of concurrent chemotherapy brings more clinical benefits for LANPC in the era of IMRT.

In this study, we conducted a meta-analysis using available evidence from randomized controlled trials to compare the efficacy and toxicity of CCRT to RT alone for LANPC in the era of IMRT.

Materials and methods
=====================

Search strategy and selection criteria
--------------------------------------

PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, Weipu Information Resources System, and Chinese Biomedical Database were searched up to August 2017. References of relevant articles were also searched carefully.

Literatures were screened for eligibility using the following criteria: 1) participating patients with non-metastatic NPC diagnosed as stage III--IVb, 2) studies comparing IMRT combined with current chemotherapy with IMRT alone, and 3) randomized controlled trials.

Reports were excluded by the following criteria: 1) republication of literature; 2) treatment included 2D-RT; 3) no randomized controlled trials or any reviews, comments, and letters; 4) concurrent targeted therapy; 5) induction chemotherapy or adjuvant chemotherapy was applied; and 6) full text was unpublished. Eligibility assessment was performed by two reviewers. Disagreements between reviewers were settled by discussion.

Data extraction
---------------

Extraction was performed by two reviewers. Disagreements were resolved by discussion. We contacted the original study researchers for indistinct data and removed the data from stage II NPC patients. The following information was extracted: first author, publication year, patient number, inclusion period, random method, treatment regimen, and outcomes. The efficient outcomes were overall response rate (ORR), complete response rate (CRR), and OS. As for the toxic outcomes, data on grade 3--4 adverse events of hematologic toxicity, gastrointestinal reaction, radiation-induced oral mucositis, and radiodermatitis were extracted. If the study reported relevant adverse events separately, for example, nausea, vomiting, and diarrhea, the higher event rate was used to approximate the overall events. Among the 15 studies, 1 study utilized Common Terminology Criteria for Adverse Events criteria 3.0 for adverse events, and the rest utilized the World Health Organization criteria. However, the evaluation standard is very similar in these two criteria for adverse events. Thus, these data could be combined in this meta-analysis.

Assessment of risk of bias and data analysis
--------------------------------------------

We assessed the risk of bias referring to the guidance of Cochrane Handbook for Systematic Reviews of Interventions (5.1.0).[@b16-cmar-10-1419] Statistical analysis was performed by Review Manager Software (RevMan 5.3; Cochrane Collaboration, Oxford, UK).

ORR, CRR, OS, and grade 3--4 advent events were analyzed quantitatively by using the risk ratio (RR), and 95% CI was calculated. RR represents the risk ratio of an event which occurred in the CCRT group versus the RT group. An observed RR \<1 and a 95% CI which did not overlap 1 with *P*\<0.05 indicated that CCRT could offer more benefits to patients with LANPC and would be considered statistically significant. Heterogeneity was used to evaluate the variability in studies by *I*^2^ statistic. If *I*^2^ statistic was \<50%, we considered the heterogeneity was acceptable, and we used the fixed-effects model for the meta-analysis. The value of *I*^2^ ≥50% was considered to indicate substantial statistical heterogeneity. The causes of heterogeneity among the results of studies were explored. Then, a random-effects model was used.

Results
=======

Search results and characteristics of studies
---------------------------------------------

A total of 1753 citations were searched by PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, Weipu Information Resources System and Chinese Biomedical Database (shown in Supplementary materials). Furthermore, possibly useful publications were hand-searched, but eligible studies were not found. One thousand three hundred and twenty citations remained after removing duplicates. After reviewing the titles and abstracts carefully, 1292 citations did not match the inclusion criteria. Finally, 28 citations remained. After reading these 28 studies carefully, 13 studies were removed. These were removed because of the following reasons: three citations were not truly randomized; in three citations, the concurrent drugs were molecular targeted therapy; one citation was a conference abstract; in three citations, adjuvant chemotherapy was administered; and in the remaining three citations, not all patients were treated with IMRT. Collectively, 15 clinical studies were available for this meta-analysis ([Figure 1](#f1-cmar-10-1419){ref-type="fig"}).[@b17-cmar-10-1419]--[@b31-cmar-10-1419]

The characteristics of the 15 studies are summarized in [Table 1](#t1-cmar-10-1419){ref-type="table"}. We included 1142 patients in the meta-analysis, of whom 573 received CCRT and 569 were allocated to IMRT alone group. Baseline characteristics were balanced in all studies. All patients included in this meta-analysis were LANPC (stage III--IVb). The concurrent chemotherapy drugs reported in these studies included cisplatin, nedaplatin, docetaxel, 5-fluorouracil, xeloda and s-1 (tegafur, gimeracil and oteracil potassium). ORR data were available in 12 studies, CRR data in 13 studies, and OS data in 6 studies. Almost all studies assessed the response rate according to Response Evaluation Criteria in Solid Tumors at 3 months after RT by magnetic resonance imaging.

Risk of bias of eligible studies
--------------------------------

Among the selected 15 studies, 9 studies were assessed as low risk of bias because these trials were assigned by the random number table. Two studies were evaluated as high risk because these two trials were assigned by the day on which a patient is admitted to the hospital. It was unclear how to generate random sequence in four studies. Allocation concealment was not clearly reported in all studies. Blinding of participants was not applied in all 15 trials because of intervention measures. Blinding of outcome assessment was not reported in 13 trials and was reported in the remaining 2 trials. Fourteen studies reported complete outcome data. One study reported lost to follow-up, but we assessed this study as low risk because the number of lost to follow-up was balanced in both groups of this study (Liu et al,[@b20-cmar-10-1419] the number of lost to follow-up in CCRT: 3, RT: 4; [Figure 2](#f2-cmar-10-1419){ref-type="fig"}). The publication bias might exist according to the funnel plots ([Figure S1](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D160469.pdf)).

Efficacy and toxicity
---------------------

Compared with RT alone group, ORR (RR 0.53, 95% CI 0.43--0.66, *P*\<0.00001; participants=946 \[CCRT:474, RT:472\]; studies=12; *I*^2^=46%) and CRR (RR 0.60, 95% CI 0.51--0.71, *P*\<0.00001; participants=968 \[CCRT:486, RT:482\]; studies=13; *I*^2^=23%) were significantly improved in CCRT group ([Figure 3](#f3-cmar-10-1419){ref-type="fig"}). CCRT also obviously prolonged 1-year OS (RR 0.44, 95% CI 0.26--0.77, *P*=0.004; participants=507 \[CCRT: 256, RT: 251\]; studies=6; *I*^2^=0%), when compared with IMRT alone. Furthermore, results showed that 3-year OS (RR 0.61, 95% CI 0.39--0.95, *P*=0.03; participants=223 \[CCRT: 113, RT: 110\]; studies=2; *I*^2^=12%) and 5-year OS (RR 0.64, 95% CI 0.45--0.91, *P*=0.01; participants=154 \[CCRT: 78, RT: 76\]; studies=2; *I*^2^=0%) were significantly prolonged in CCRT group ([Figure 4](#f4-cmar-10-1419){ref-type="fig"}). Among these 15 papers, 3 reported distant metastasis rate, and all showed that the addition of concurrent chemotherapy contributed to a significant decrease in distant metastasis rate, compared with IMRT alone.[@b21-cmar-10-1419],[@b25-cmar-10-1419],[@b29-cmar-10-1419]

In CCRT group, higher grade 3--4 adverse reaction was observed in hematologic toxicity (RR 2.25, 95% CI 1.54--3.29, *P*\<0.0001; participants=627 \[CCRT: 316, RT: 311\]; studies=9; *I*^2^=42%), radiation-induced oral mucositis (RR 1.64, 95% CI 1.14--2.35, *P*=0.007; participants=469 \[CCRT: 237, RT: 232\]; studies=7; *I*^2^=8%) and radiodermatitis (RR 1.80, 95% CI 1.13--2.88, *P*=0.01; participants=469 \[CCRT: 237, RT: 232\]; studies=7; *I*^2^=14%), as shown in [Figure 5](#f5-cmar-10-1419){ref-type="fig"}. Only grade 3--4 gastrointestinal reaction (RR 1.19, 95% CI 0.14--9.82, *P*=0.87; participants=579 \[CCRT: 292, RT: 287\]; studies=8; *I*^2^=86%) was not significantly different between these two groups. We observed that grade 3--4 gastrointestinal reaction had obvious heterogeneity. Subgroup analyses were conducted ([Figure S2](https://www.dovepress.com/get_supplementary_file.php%3Ff%3D160469.pdf)), and results showed that heterogeneity was obviously decreased in the subgroup using different chemotherapy regimens. Cisplatin-based concurrent chemotherapy indicated higher grade 3--4 gastrointestinal reaction in CCRT group than in RT group, while no obvious increase of grade 3--4 gastrointestinal reaction was found in nedaplatin-based studies.

We performed a sensitivity analysis by excluding each study once in all of the genetic models. No obvious influence on final results, including ORR, CRR, OS and grade 3--4 adverse reaction, was observed after excluding each study.

Discussion
==========

NPC has an uneven worldwide distribution and a high incidence rate is found in Southeast Asia.[@b1-cmar-10-1419] RT is the main treatment for NPC. However, the 5-year OS rate for LANPC is only 67%--77% by utilizing 2D-RT.[@b3-cmar-10-1419] With the development of RT technology, IMRT is recommended to treat NPC because it brings better tumor target coverage and less radiation-associated toxicities.[@b6-cmar-10-1419],[@b7-cmar-10-1419],[@b32-cmar-10-1419] In the era of IMRT, it is unclear whether adding concurrent chemotherapy provides additional benefits for LANPC.

In this meta-analysis, all included studies were prospective randomized controlled studies. The analysis results pooling 15 clinical studies indicated that concurrent chemotherapy plus IMRT contributed to better prognosis than IMRT alone. CCRT significantly improved ORR, CRR, and OS. As for the treatment-associated toxicities, CCRT led to more tolerated adverse events compared with IMRT alone.

Previous published meta-analyses showed that the addition of concurrent chemotherapy improved prognosis in LANPC patients in the era of 2D-RT. For example, it was reported that the 5-year OS was significantly improved after the addition of concurrent chemotherapy in a meta-analysis from 16 trials involving 2576 patients with LANPC, when compared with RT alone.[@b33-cmar-10-1419] Furthermore, a meta-analysis, pooling the data of NPC in endemic areas, showed that CCRT group also improved the 5-year OS, compared with RT alone.[@b34-cmar-10-1419] In terms of toxicities, the addition of concurrent chemotherapy is associated with higher incidences of acute and late toxicities. It was shown that cisplatin-based chemotherapy combined with RT increased the risk of treatment-related death and acute toxicities, and the overall incidence rates of treatment-related mortality in CCRT and RT alone were 1.7% and 0.8%, respectively.[@b35-cmar-10-1419] Moreover, the overall incidence of late toxicities was 30.7% in CCRT group, while it was 21.7% in RT alone group.[@b36-cmar-10-1419] In these meta-analyses, the radiation mainly utilized 2D-RT methods, and a very small group of patients were treated with IMRT. These data are consistent with our conclusions that concurrent chemotherapy improves OS in LANPC, compared with IMRT alone.

To our knowledge, this is the first meta-analysis focusing on comparing the efficacy and toxicity of CCRT to IMRT alone for LANPC. This meta-analysis has several limitations. First, randomization method and allocation concealment were not reported in all included studies. Second, the recruited patient population was small in these included studies. Third, the median follow-up time is not long enough in some trials. Thus, we need multicenter randomized controlled trials and long-term follow-up to evaluate the eventual efficacy and toxicity of concurrent chemotherapy plus IMRT.

In conclusion, in the era of IMRT, current evidences show that compared with RT alone, CCRT still brings clinical benefit in LANPC with acceptable toxicities.
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**Note:** (**A**) Hematologic toxicity, (**B**) radiation-induced oral mucositis, (**C**) radiodermatitis, and (**D**) gastrointestinal reaction.\
**Abbreviations:** CCRT, concurrent chemoradiotherapy; *df*, degrees of freedom; IMRT, intensity-modulated radiotherapy; M--H, the Mantel--Haenszel method; RT, radiotherapy.](cmar-10-1419Fig5){#f5-cmar-10-1419}

###### 

Characteristics of included studies

  Studies                                      Inclusion period                 Patients (n)   Mean age      Gender (M:F)   Treatment arm                 Stage                      Radiotherapy doses           Concurrent chemotherapy
  -------------------------------------------- -------------------------------- -------------- ------------- -------------- ----------------------------- -------------------------- ---------------------------- ------------------------------------------------
  Chen et al,[@b17-cmar-10-1419] 2017          January 2011 to August 2015      32             72.96±2.45    24:8           RT                            Stage III--IVa             GTVnx: 70--76 Gy/28f         S-1 60 mg/m^2^, bid, d1--28, q6w
  34                                           73.27±2. 12                      25:9           CCRT                         GTVnd: 66--70 Gy/28f                                                                  
                                                                                                                            CTV1: 50.8--60 Gy/28f                                                                 
                                                                                                                            CTV2: 50.8 Gy/28f                                                                     
  Li et al,[@b18-cmar-10-1419] 2010            April 2006 to April 2008         40             48 (25--78)   60:20          RT                            Stage III--IVa             GTVnx: 73.9 Gy/33f           DDP 80 mg/m^2^, d1, d22, d43
  40                                                                                           CCRT                         GTVnd, CTV1: 66 Gy/33f                                                                
                                                                                                                            CTV2: 50.4--59.4 Gy/28--33f                                                           
  Liu et al,[@b20-cmar-10-1419] 2012           February 2005 to March 2008      41             55 (18--76)   28:13          RT                            Stage III--IVb             GTV: 70 Gy/32--33f           Xeloda 500 mg/m^2^ bid
  44                                                                            35:9           CCRT                         CTV1: 64--66 Gy/32--33f                                                               
                                                                                                                            CTV2: 54--56 Gy/30--32f                                                               
  Tian and You-Ming,[@b22-cmar-10-1419] 2014   January 2006 to January 2012     24             53 (34--74)   27:21          RT                            Stage III                  GTV: 68--74 Gy/35--37f       Docetaxel 20--25 mg/m^2^, 7 weeks
  24                                                                                           CCRT                         CTV: 60--70 Gy/6--7 weeks                                                             
  Wang et al,[@b23-cmar-10-1419] 2008          January 2006 to October 2007     25             44 (20--67)   18:7           RT                            Stage III--IVb             GTVnx: 74--78 Gy             Xeloda 750--1000
  25                                           48 (18--68)                      19:6           CCRT                         GTVnd: 70 Gy                  mg/m^2^, d1--14, d28--42                                
                                                                                                                            CTV1: 60--66 Gy                                                                       
                                                                                                                            CTV2: 51--56 Gy                                                                       
  Wang et al,[@b33-cmar-10-1419] 2016          February 2013 to February 2015   47             45 (20--60)   59:35          RT                            Stage III--IVb             N/A                          Docetaxel 65 mg/m^2^ d1, NDP 80 mg/m^2^ d1--5
  47                                                                                           CCRT                                                                                                               
  Wang et al,[@b24-cmar-10-1419] 2014          January 2011 to January 2012     30             45.45±5.83    18:12          RT                            Stage III--IVb             GTV: 70 Gy/35f               S-1 80 mg/m^2^, bid, d1--14, q3w
  30                                           45.23±5.67                       20:10          CCRT                                                                                                               
  Wei et al,[@b25-cmar-10-1419] 2015           April 2012 to March 2014"        39             50.6±7.4      26:13          RT                            Stage III--IVb             GTVnx, GTVnd: 65--71 Gy      Docetaxel d1, NDP d1, q2w
  39                                           51.1±6.8                         25:14          CCRT                         CTV1: 55 Gy                                                                           
                                                                                                                            CTV2: 53 Gy                                                                           
  Xie et al,[@b26-cmar-10-1419] 2011           February 2006 to April 2007      30             46 (22--70)   19:11          RT                            Stage III--IVb             GTVnx, GTVnd: 69--76         DDP 60 mg/m^2^ d1, 5-FU 750 mg/m^2^ d2--4, q3w
  30                                           49 (17--71)                      21:9           CCRT                         Gy/32f                                                                                
                                                                                                                            CTV1: 60--65 Gy/32f                                                                   
                                                                                                                            CTV2: 50--60 Gy/28f                                                                   
  Xu,[@b27-cmar-10-1419] 2014                  July 2013 to May 2014            34             50.8±17.5     20:14          RT                            Stage III--IVb             GTV: 66--70 Gy/30--33f       DDP 20 mg/m^2^, 5-FU 750 mg/m^2^
  35                                           64.2±3.5                         25:10          CCRT                                                                                                               
  Zhang et al,[@b34-cmar-10-1419] 2016         January 2013 to January 2014     40             63.8±3.1      26:14          RT                            Stage III--IVa             GTVnx: 70--75.9 Gy/30--33f   NDP 80 mg/m^2^ d1, d28
  40                                           64.2±3.5                         24:16          CCRT                         GTVnd: 66--70.4 Gy/30--33f                                                            
                                                                                                                            CTV1: 60--64 Gy/30--33f                                                               
                                                                                                                            CTV2: 50--54 Gy/30--33f                                                               
  Zhen et al,[@b31-cmar-10-1419] 2015          June 2008 to June 2012           60             73.5±2.6      31:29          RT                            Stage III--IVb             N/A                          S-1 40--60 mg·m^2^
  60                                           73.6±2.5                         31:29          CCRT                                                                                                               
  Liu et al,[@b21-cmar-10-1419] 2015           February 2010 to February 2011   69             42.5±15.8     35:34          RT                            Stage III--IVb             GTVnx: 69.96--73.92 Gy       NDP 40 mg/m^2^ d1--5
  69                                           43.1±16.2                        36:33          CCRT                         GTVnd: 69.96 Gy                                                                       
                                                                                                                            CTV1: 60.06--66 Gy                                                                    
                                                                                                                            CTV2: 50.96--56 Gy, 7 weeks                                                           
  Zheng,[@b30-cmar-10-1419] 2010               N/A                              17             40 (20--65)   21:13          RT                            Stage III--IVb             GTVnx: 72.6 Gy               DDP 20 mg/m^2^, d1--5
                                               17                                                            CCRT                                         GTVnd: 69.96 Gy            5-FU 500 mg/m^2^, d1--5      
                                                                                                                                                          CTV1: 60.06 Gy                                          
                                                                                                                                                          CTV2: 50.96 Gy, 7 weeks                                 
  Yuan et al,[@b29-cmar-10-1419] 2016          May 2012 to June 2015            40             51.32±5.29    23:17          RT                            Stage III--IVb             N/A                          Docetaxel 60 mg/m^2^, Nedaplatin, q2w
  40                                           51.25±5.34                       22:18          CCRT                                                                                                               

**Abbreviations:** 5-FU, 5-fluorouracil; bid, twice daily; CCRT, concurrent chemoradiotherapy; CTV, clinical target volume; DDP, cisplatin; d, day; F, female; GTV gross tumor volume; IMRT, intensity-modulated radiotherapy; M, male; N/A, not available; NDP, nedaplatin; q2w, every 2 weeks; q3w, every 3 weeks; q6w, every 6 weeks; RT, intensity-modulated radiotherapy alone.
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